BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Thyroscope and TORC strategically collaborate to advance AI-driven precision medicine in thyroid eye disease

November 19, 2026 | News

Smartphone monitoring, quantitative orbital imaging and clinical data will support a planned longitudinal study and a TORC-led research database



South Korea-based Thyroscope and The Orbital Radiology Center (TORC) have announced a Memorandum of Understanding to investigate an integrated approach to monitoring thyroid eye disease (TED) using smartphone-based artificial intelligence, quantitative orbital imaging and longitudinal clinical data.

Thyroscope will contribute its Glandy smartphone-based AI platform for monitoring patients between clinical visits, while TORC will provide quantitative orbital imaging expertise. Together, the partners will develop a multimodal TED research database integrating smartphone-based assessments, quantitative imaging and longitudinal clinical data. BioSight Innovations, also led by TORC CEO Dr Shoaib Ugradar, will provide treatment sites, clinical assessments and longitudinal follow-up for the initial study.

TORC has provided contracted imaging assessment services for four clinical trials sponsored by Viridian Therapeutics, Zenas BioPharma, Lassen Therapeutics and Immunovant, and for an Amgen post-marketing study. Its scientific work includes nine published papers on quantitative imaging in TED.

TED is an autoimmune disease that can cause inflammation, proptosis, eyelid retraction, double vision and, in severe cases, irreversible vision loss. Despite expanding treatments, assessment still relies on scheduled clinic visits. Measurements such as proptosis and the Clinical Activity Score (CAS) may vary between assessors and do not fully capture changes within orbital tissues.
The partners will study whether home measurements and imaging improve longitudinal assessment.